Cyclopharm Ltd
(ASX:CYC) Share Price and News
Key Statistics
Introduction to Cyclopharm
Cyclopharm (ASX:CYC) is a radiopharmaceutical company that is responsible for Technegas, a proprietary functional lung ventilation imaging agent.
Essentially, a patient inhales Technegas before undertaking a Ventilation-Perfusion (VQ) scan and it makes the lungs easier to see. The company makes revenues through Technegas generators, but also through consumables and after-sales services of the devices. Technegas is not only less damaging than alternative agents but is highly accurate, is quick and simple to administer and has minimal exclusion criteria (in other words, it can be administered to almost all patients including those with chronic lung obstruction disease).
Technegas is approved and/or sold in over 60 countries globally, a list that has only included the USA since October 2023. 2024 is set to be a key year for the company as it enters the world's largest healthcare market.
Cyclopharm Company History
Technegas was discovered in the mid 1980s and was registered as a drug in Europe in 1996. In 2003-2005, it entered the Canadian market which has grown to be the largest individual nation for Technegas by sales and the company has captured virtually all of the market.
Cyclopharm was incorporated in 2005 and bought Technegas from Vita Life in 2006 via a share exchange. The company listed on the ASX in 2007. For several years, the company strived to gain FDA approval and enter the US market, but it only got the green light in October 2023.
Future Outlook of Cyclopharm Ltd (ASX: CYC)
Cyclopharm has a bright future ahead of it now that it has FDA approval. The company estimates that there is a market opportunity of US$90m or 600,000 procedures. Cyclopharm is targeting 80% of these, or 480,000 of these and believes it can achieve a 50% market share in 2-3 years and 90% in 5-7 years.
Cyclopharm is also seeking to expand the use of Technegas against other indications that could be larger markets - including COPD, asthma and Long COVID.
Is Cyclopharm (ASX: CYC) a Good Stock to Buy?
Yes. There are few other biotech stocks to have recently achieved FDA approval, have the market right in its grasp and has a proven track record of entering new markets.
Our Stock Analysis
What are the best ASX Health Stocks for 2024? Here are our top 4 picks!
As 2023 comes to an end, we thought we’d recap our best ASX Health Stocks for 2024! Traditionally, healthcare stocks…
FDA approval: Here’s how ASX biotechs and medtechs obtain it
Last week one of our favourite companies Cyclopharm (ASX:CYC) obtained FDA approval, a goal it had been striving for years…
The 3 best ASX biotech stocks for September!
Here are a trio of companies that we think are the best ASX biotech stocks for September! What are…
Why did biotech shares underperform in 2022 and will they rebound with a vengence in 2023?
In the past year, biotech shares have performed poorly. Why has this been the case and will things be better…
Which ASX health stocks might get FDA approval in 2023?
It is the dream of many ASX health stocks and their investors for their company’s device or drug to be…
Frequently Asked Questions
Technegas® is Cyclopharm's flagship product, a unique diagnostic agent used in lung ventilation imaging, crucial for diagnosing pulmonary embolism and other respiratory conditions.